COMMUNIQUÉS West-GlobeNewswire

Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct® Platform
12/03/2026
Companies deepen partnership to advance automated, integrated microbiology quality control LEXINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative [...]
Koelis Announces Innovative Products at EAU 2026 enhancing MRI Fusion Biopsy Workflows and promoting Focal Therapy in Prostate Cancer
12/03/2026
GRENOBLE, France, March 12, 2026 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com ), a leader and innovator in MRI-ultrasound fusion guidance for prostate cancer interventions, announced today [...]
Verano Announces $195 Million Senior Secured Term Loan Refinancing Agreement to Fund Company’s Strategic Growth Initiatives
12/03/2026
New credit facility highlights Company’s ability to access lower-cost regional bank capital and secure among the most favorable terms in the industry, including an initial 9.5% annual interest rate and prepayment [...]
Aplagon Announces First Patient Dosed in Phase 2a Clinical Trial of APAC in Patients with Peripheral Arterial Occlusive Disease / Chronic Limb Threatening Ischemia
12/03/2026
HELSINKI, March 12, 2026 (GLOBE NEWSWIRE) -- Aplagon , a clinical stage biotech pioneering a first-in-class treatment for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet [...]
Demande d’autorisation de mise sur le marché de TECVAYLI®▼ (teclistamab) en monothérapie soumise à l’EMA pour le myélome multiple en rechute ou réfractaire après au moins une ligne de traitement antérieure
12/03/2026
Application appuyée par des données de la Phase 3 renforçant les schémas thérapeutiques à base de teclistamab comme traitement standard potentiel après au moins une thérapie antérieure 1 La monothérapie par teclistamab [...]
Bavarian Nordic Launches Next Tranche of Share Buy-Back Program
12/03/2026
COPENHAGEN, Denmark, March 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the second tranche of the planned buy-back program, under which the Company intends to repurchase own shares for up to DKK 500 million [...]
Allegro’s osteoarthritis hydrogel resolves lameness in animal study
12/03/2026
The hydrogel resolved lameness in 72% of horses treated Horses provide a strong translational model for human osteoarthritis Clinical investigation authorized by Belgian regulatory authority Allegro’s hydrogel is first- [...]
Full Year 2025 Trading Update
12/03/2026
Ad hoc announcement pursuant to Art. 53 LR AGAMREE continues to build strong commercial momentum, delivering 98% revenue growth Pratteln, Switzerland, March 12, 2026 – Santhera Pharmaceuticals (SIX: SANN) today provides [...]
Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow
12/03/2026
Full year 2025 total revenues increased by 27% to US$376.1 million, driven by continued growth of RUCONEST® and rising demand for Joenja® (leniolisib) Fourth quarter 2025 total revenues increased by 15% to US$106.5 [...]
Ipsen appoints Michelle C. Werner as EVP, President of North America
12/03/2026
PARIS, FRANCE, 12 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Michelle C. Werner as Executive Vice President (EVP), President of North America, effective 23 March 2026. Michelle [...]
BioVersys Announces First Patient Dosed in Phase 2b Clinical Trial of AlpE in Pulmonary Tuberculosis
12/03/2026
Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, March 12, 2026 (GLOBE NEWSWIRE) -- Under the BioVersys and GSK collaboration agreement, AlpE clinical development advances with first patient dosed in Phase [...]
Bavarian Nordic Publishes Annual Report 2025
12/03/2026
COPENHAGEN, Denmark, March 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) today published its annual report for 2025. The consolidated, audited results were in line with the preliminary results announced on February 12, [...]
Novo Holdings announces 2025 Annual Results
12/03/2026
Total Income and Investment Returns in 2025 were DKK 21 billion (€2.8 billion). For 2025, Total Income and Investment Returns consisted of Income from dividends from the Novo Group companies (DKK 15 billion or €2.0 [...]
Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
12/03/2026
NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD [...]
Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform
11/03/2026
WARREN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today issued a statement from Founder and CEO Dr. Ryan Saadi regarding the company’s progress in [...]
Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results
11/03/2026
Q4 revenue of $38.9 million, total revenue of $70.4 million for the fiscal year ended December 31, 2025 Ended year with $78.2 million in cash, cash equivalents and short-term investments, runway through 2027 Completed $ [...]
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
11/03/2026
PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors PLN-101095 accelerated development plan underway with initiation of Phase 1b indication expansion trial [...]
Rad Source Technologies Announces Configurable Filters for the RS® 2000·Q2 Biological Irradiator
11/03/2026
BUFORD, Ga., March 11, 2026 (GLOBE NEWSWIRE) -- Rad Source Technologies (Rad Source ® ), a global leader in advanced X‑ray solutions for life sciences, today announced the launch of Configurable Filters for the RS ® [...]
Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process
11/03/2026
– Base biologic matrix NXT-41 submitted to FDA; on track for anticipated FDA clearance in second half of 2026 and full NXT-41x clearance in 1H27 – – $44.4 million in cash and escrowed proceeds at year-end – – Conference [...]

Pages